Correction: Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer (Cancer Research (2015)75 (2292–2304) DOI: 10.1158/0008-5472.CAN-14-2397);Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2292-2304

  Khan, Sheema ^a   Ebeling, Mara C ^b   Chauhan, Neeraj ^a   Thompson, Paul A ^b   Gara, Rishi K ^a   Ganju, Aditya ^a   Yallapu, Murali M ^a   Behrman, Stephen W ^a   Zhao, Haotian ^b   Zafar, Nadeem ^a   Singh, Man Mohan ^c   Jaggi, Meena ^a   Chauhan, Subhash C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b SANFORD RESEARCH   (United States)

^c SARASWATI DENTAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CENTCHROMAN; COLLAGEN TYPE 1; CYCLIN D1; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 132; PROTEIN KINASE B; PROTEIN PATCHED 1; PROTEIN PATCHED 2; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; BENZOPYRAN DERIVATIVE; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DESMOPLASIA; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; STELLATE CELL; STROMA; STROMA CELL; TISSUE GROWTH; TUMOR XENOGRAFT; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BENZOPYRANS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MICE; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941226357     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-0427     Document Type: Erratum

References (50)

1. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefitwith gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
2. Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the royal marsden experience. Clin Colorectal Cancer 2014; 13:232-8.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
5. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-6.
6. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004;29:179-87.
7. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008;14:5995-6004.
8. Pasca di MaglianoM, HebrokM. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003;3:903-11.
9. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6.
10. Merchant AA, Matsui W. Targeting hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40.
11. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Gene Dev 2008;22:2454-72.
12. Kelleher FC. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 2011;32:445-51.
13. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61.
14. Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014;20:5937-45.
15. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
16. Juhasz ML, Marmur ES. Systematic review of vismodegib toxicity profile in the treatment of advanced Basal cell carcinomas compared to other systemic therapies in dermatology. J Drugs Dermatol 2014;13:729-33.
17. Sheikh A, Alvi AA, Aslam HM, Haseeb A. Hedgehog pathway inhibitors- current status and future prospects. Infect Agent Cancer 2012;7:29.
18. Gara RK, Sundram V, Chauhan SC, Jaggi M. Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem 2013;20:4177-84.
19. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 2001;21:302-47.
20. Lipinski RJ, Hutson PR, Hannam PW, Nydza RJ, Washington IM, Moore RW, et al. Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. Toxicol Sci 2008;104:189-97.
21. LoRusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced ormetastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharm 2013;71:193-202.
22. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE 2011;6:e16530.
23. Ji X MY, Liu Y, Jin T, Song P. J Chin Pharm Sci 1998;7:69-71.
24. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS ONE 2012;7:e46536.
25. Khan S, Kaur R, Shah BA, Malik F, Kumar A, Bhushan S, et al. A Novel cyano derivative of 11-Keto-beta-Boswellic acid causes apoptotic death by disrupting PI3K/AKT/Hsp-90 cascade, mitochondrial integrity, and other cell survival signaling events in HL-60 cells. Mol Carcinogen 2012;51:679-95.
26. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
27. Berna MJ, Seiz O, Nast JF, Benten D, Blaker M, Koch J, et al. CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem 2010;285:38905-14.
28. Chauhan SC, Ebeling MC, MaherDM, Koch MD, Watanabe A, Aburatani H, et al. MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther 2012;11:24-33.
29. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, et al. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget 2014;5:7599-609.
30. YallapuMM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther 2013;12:1471-80.
31. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 2009;16: 712-23.
32. Dunaeva M, Michelson P, Kogerman P, Toftgard R. Characterization of the physical interaction of Gli proteins with SUFU proteins. J Biol Chem 2003;278:5116-22.
33. Kasperczyk H, Baumann B, Debatin KM, Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB- mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009;23: 21-33.
34. Morton JP, Mongeau ME, Klimstra DS, Morris JP, Lee YC, Kawaguchi Y, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 2007;104:5103-8.
35. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991;65:701-13.
36. Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 2003;5:130-5.
37. LiuM, Xu J, DengH. Tangled fibroblasts in tumor-stroma interactions. Int J Cancer 2011;129:1795-805.
38. Singh AP, Arora S, Bhardwaj A, Srivastava SK, Kadakia MP, Wang B, et al. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor kappaB: implications for bidirectional tumor-stromal interactions. J Biol Chem 2012;287: 39115-24.
39. Zhang S, Hao J, Xie F, HuX, Liu C, Tong J, et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011;32:1183-9.
40. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331: 1612-6.
41. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.
42. Merika EE, Syrigos KN, Saif MW. Desmoplasia in pancreatic cancer. Canwe fight it? Gastroenterol Res Pract 2012;2012:781765.
43. Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 2009;28:3513-25.
44. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreatedmetastatic colorectal cancer. Clin Cancer Res 2013;19:258-67.
45. Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS Lett 2012;586:2016-25.
46. Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012;72:5048-59.
47. Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y, et al. Curcumin inhibits the sonic hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinogen 2010;49:302-14.
48. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007;104:5895-900.
49. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
50. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53.